CGEM · Cullinan Therapeutics, Inc.

$21.68 +0.30 (+1.40%) At close · Aug 21

Market Cap

$1.38B

64.35M

Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.

Equity Offering (ATM) Programs

Program Established	Last Amended	Capacity	Sold	Remaining	Runs Through	Source
2026-04	—	$200,000,000	—	—	—	10-Q , filed 2026-08-06
—	—	$125,000,000	3,300,000 shares as of 2025-09-30	$85,600,000 as of 2025-09-30	—	10-Q , filed 2025-11-06

Cash spent on buybacks by quarter

Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.

Repurchase History

Fiscal Year Ended	Cash Spent	Shares	Avg Price	Source
2020-12-31	$6,572,000	—	—	10-K, filed 2022-03-17

Quarter Ended	Cash Spent	Shares	Avg Price	Source
2020-12-31	$6,359,000 Δ	—	—	10-K, filed 2022-03-17
2020-09-30	$0 Δ	—	—	10-Q, filed 2021-11-09
2020-06-30	$0 Δ	—	—	10-Q, filed 2021-08-10
2020-03-31	$213,000	—	—	10-Q, filed 2021-05-14

Key facts CIK 1789972 CUSIP 230031106 13F (30d) 172 filings 170 filers Visit website Investor relations